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Abstract
AIM: To evaluate the effect of portal vein thrombosis 
and arterioportal shunts on local tumor response in 
advanced cases of unresectable hepatocellular carcinoma 
treated by transarterial chemoembolization. 
METHODS: A retrospective study included 39 patients 
(mean age: 66.4 years, range: 45-79 years, SD: 7) with 
unresectable hepatocellular carcinoma (HCC) who were 
treated with repetitive transarterial chemoembolization 
(TACE) in the period between March 2006 and October 
2009. The effect of portal vein thrombosis (PVT) (in 19 
out of 39 patients), the presence of arterioportal shunt 
(APS) (in 7 out of 39), the underlying liver pathology, 
Child-Pugh score, initial tumor volume, number of tumors 
and tumor margin definition on imaging were correlated 
with the local tumor response after TACE. The initial 
and end therapy local tumor responses were evaluated 
according to the response evaluation criteria in solid 
tumors (RECIST) and magnetic resonance imaging 
volumetric measurements.
RESULTS: The treatment protocols were well tolerated 
by all patients with no major complications. Local tumor 
response for all patients according to RECIST criteria 
were partial response in one patient (2.6%), stable 
disease in 34 patients (87.1%), and progressive disease 
in 4 patients (10.2%). The MR volumetric measurements 
showed that the PVT, APS, underlying liver pathology 
and tumor margin definition were statistically significant 
prognostic factors for the local tumor response (P = 
0.018, P = 0.008, P = 0.034 and P = 0.001, respectively). 
The overall 6-, 12- and 18-mo survival rates from the 
initial TACE were 79.5%, 37.5% and 21%, respectively.
CONCLUSION: TACE may be exploited safely for palliative 
tumor control in patients with advanced unresectable 
HCC; however, tumor response is significantly affected 
by the presence or absence of PVT and APS. 
© 2011 Baishideng. All rights reserved.
Key words: Hepatocellular carcinoma; Transarterial 
chemoembolization; Portal; Shunt; Thrombosis
Peer reviewer: Satoshi Mamori, MD, PhD, Department of 
Gastroenterology and Hepatology, Shinko Hospital, 1-4-47 
Wakihama-cho, Chuo-ku, Kobe, Hyogo 651-0072, Japan
Vogl TJ, Nour-Eldin NE, Emad-Eldin S, Naguib NNN, 
Trojan J, Ackermann H, Abdelaziz O. Portal vein thrombosis 
and arterioportal shunts: Effects on tumor response after 
chemoembolization of hepatocellular carcinoma. World J 
Gastroenterol 2011; 17(10): 1267-1275  Available from: URL: 
1267
World J Gastroenterol  2011 March 14; 17(10): 1267-1275
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2011 Baishideng. All rights reserved.
Online Submissions: http://www.wjgnet.com/1007-9327office
wjg@wjgnet.com
doi:10.3748/wjg.v17.i10.1267
March 14, 2011|Volume 17|Issue 10| WJG|www.wjgnet.comVogl TJ et al. TACE therapy in advanced HCC
http://www.wjgnet.com/1007-9327/full/v17/i10/1267.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v17.i10.1267
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most 
common neoplasms in the world and its incidence is 
increasing worldwide. It is associated with liver cirrhosis in 
80% of cases and it is the leading cause of death among 
cirrhotic patients
[1]. Liver resection and liver transplantation 
are curative therapeutic options
[2]. Likewise, percutaneous 
ablative treatments such as percutaneous ethanol injection 
(PEI)
[3], radiofrequency ablation
[4], microwave ablation
[5] 
or MR-guided laser-induced thermotherapy (LITT)
[6] 
can also be applied as therapeutic options with curative 
potential. However, curative treatments are applicable 
in only 30%-40% of cases due to the presence of mu-
ltifocal tumors or limited hepatic reserve at the time of 
diagnosis
[7,8]. Transarterial chemoembolization (TACE) 
was introduced as a palliative local therapeutic option for 
the treatment of unresectable HCC. The goal of palli-
ation is to control symptoms, improve life quality and 
prolong survival
[8,9]. Different studies have investigated 
the predictors of survival after TACE and concluded that 
the prognosis is multifactorial, including the extent of the 
tumor at diagnosis and also the extent of liver injury
[8,10,11].
The purpose of this study was to evaluate retrospec-
tively the role of TACE in local tumor control of unre-
sectable HCC and the effect of portal vein thrombosis 
(PVT) and arterioportal shunts (APS), as well as other as-
sociated pathological factors, on the local tumor response 
in advanced cases.
MATERIALS AND METHODS
Approval of this study was obtained from the institutional 
review board, and informed consent was obtained from 
all patients including approval of the protocol of treat-
ment and the anonymous use of the data for research 
purposes.
Patients
The medical records of all patients who had unresect-
able hepatocellular carcinoma and who were treated with 
TACE between March 2006 and October 2009 were 
retrospectively evaluated. A total of 39 patients (33 males 
and 6 females) ranging in age from 45-79 years (mean: 
66.4 years, SD: 7) with unresectable HCC were treated 
with repetitive TACE. The total number of sessions was 
219, range: 1-17, mean: 5.6 sessions, SD: 3.7. Patient de-
mographics, lesion pathology, treatment, and outcome 
data, including all histopathology reports and imaging 
studies, were collected from the electronic medical record 
archiving system and were subsequently analyzed. Special 
emphasis was placed on the stage of disease at the time 
of first embolization. The number, location and size of 
liver tumors were obtained by reevaluating the original CT 
and magnetic resonance imaging (MRI) scans. The patient 
and tumor characteristics are summarized in Table 1.
Inclusion and exclusion criteria
All patients involved in the study were not eligible for 
surgical or local ablative therapies. The inclusion criteria 
of the study were: (1) Tumors of any size associated with 
portal vein thrombosis, either partial thrombosis of the 
main portal vein or segmental portal vein branch throm-
bosis; (2) Tumors associated with APS with or without 
PVT; (3) Large solitary tumors of more than 5 cm in 
maximal diameter, multinodular or bilobar tumors; and (4) 
Patients with Child-Pugh Scores between A and B.
The exclusion criteria were: (1) Patients with poor per-
formance status (Karnofsky index < 50%); (2) Nutritional 
impairment; (3) Presence of ascites; (4) Encephalopathy 
(5) High serum total bilirubin level (> 3 mg/dL); (6) Se-
rum albumin level < 2.0 mg/dL; (7) Renal failure (serum 
creatinine level > 2 mg/dL); (8) Cardiovascular or respira-
tory failure; (9) Florid infection; (10) Main PV complete 
thrombosis; and (11) Extrahepatic tumor manifestation. 
Management protocol of the patients
The protocol for management was decided by a multidis-
ciplinary team composed of hepat ic surgeons, interven-
tional radiologists, hepatologists and medical oncologists. 
The end point of TACE therapy was defined as stable 
disease for two successive sessions or disease progression.
TACE technique
TACE was performed with a treatment interval of 4- 
6 wk. For patients with bilobar disease, the treatment was 
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Table 1  Patient and tumor criteria (n)  
Total number 39
Age (yr) Range: 45-79,  mean: 66.4, SD: 7
Gender (M:F) 33:6
Underlying liver pathology
Hepatitis C virus 17 
Hepatitis B virus   5 
Alcoholic cirrhosis   7 
Toxic cirrhosis   2 
Cryptogenic cirrhosis   8 
Child-Pugh Score
Child A 27 
Child B 12 
Tumor  number
Solitary 20
Multiple 19
2 lesions   6
3 lesions   3
4 lesions   1
> 5 lesions   9
Tumor margin definition
Well defined margin 20
Ill defined margin 19
Portal vein thrombosis 19
Main (partial thrombosis)   3
Main lobar branch 10
Segmental branch   6
A-P shunt   7performed to control disease in the lobe with higher tumor 
burden as seen on MRI performed immediately before the 
procedure; the second lobe was treated in another session. 
All angiographies were performed on an Axiom Multistar 
system (Siemens; Erlangen). After the introduction of a 5 
French sheath into a femoral artery, an angiographic sur-
vey of the abdominal vessels was performed using a 5 F 
pigtail catheter in the first TACE course. After exclusion 
of the presence of a right hepatic artery by selective cath-
eterization of the mesenteric artery, indirect portography 
followed, outlining the portal circulation in the venous 
phase. Afterwards, a 5 French Cobra catheter was placed in 
the coeliac trunk and advanced beyond the gastroduodenal 
artery. If possible, the tip of the catheter was advanced 
further into segmental arteries adjacent to the tumor.
The embolization suspension, containing 5-10 mg/m
2 
mitomycin C as a chemotherapeutic agent and 1-10 mL 
Lipiodol, an iodized oil, was administered, followed by 
injection of 60-180 mg degradable starch microspheres 
(EmboCept, PharmaCept) for vascular occlusion. The 
embolization material was injected slowly with fluoro-
scopic control until stasis of blood flow was observed. 
Devascularization after embolization was confirmed by 
an additional angiographic study of the hepatic artery.
Follow up after TACE
TACE procedure was performed on an outpatient basis. 
After the procedure, patients were observed for 10-12 h 
to ensure adequate hydration and symptomatic treatment 
of pain and vomiting. After the observation time, patients 
who had remained symptom-free were discharged to the 
care of the referring oncologist. If complications devel-
oped, patients were to be readmitted immediately. Com-
plications were evaluated adopting the Society of Inter-
ventional Radiology (SIR) criteria
[12]. Major complications 
were defined as any event that resulted in additional treat-
ment including an increased level of care, hospital stay be-
yond observation status (including readmission after initial 
discharge, substantial morbidity and disability and death. 
All other complications were classified as minor.
Local tumor response 
The local tumor response to the treatment protocol was 
evaluated using the response evaluation criteria in solid 
tumors (RECIST) and MRI volumetric assessment. 
According to RECIST criteria, complete response was 
defined as the complete disappearance of all recognizable 
tumor in the liver confirmed at 4 wk after the procedure. 
Partial response was defined as a reduction of at least 
30% in the sum of the longest diameter of the lesions, 
taking as reference the baseline study, and was confirmed 
at 4 wk. Stable disease was defined when neither partial 
response nor progressive disease criteria were met, tak-
ing as reference the smallest sum of the longest diameter 
recorded since treatment started. Progressive disease was 
defined as the appearance of new lesions or as an increase 
of at least 20% in the sum of the longest diameter of the 
lesions, taking as reference the smallest-sum longest diam-
eter recorded since treatment started
[13]. 
To evaluate the local tumor response using volumet-
ric MRI measurements, tumor volumes were calculated 
before treatment, one month after the first TACE ses-
sion and after the last TACE session. Tumor volumes 
were calculated with the ellipsoidal volume formula: 
Volume = (length × width × height × 0.523). For assess-
ment of multicentric tumors; in patients with up to 3 fo-
cal lesions, the sum of all tumor volumes was calculated. 
For patients with more than 3 tumors, the sum of the 
largest 3 tumors was calculated. 
The percentage of volume changes before and after 
treatment was then calculated. The local tumor response 
was considered as progressive if there was increase in 
the post-treatment volume (after the last TACE session) 
compared to the pretreatment volume, and as regressive 
if there was reduction in the post-treatment volume com-
pared to the initial volume.
Imaging technique
The morphologic tumor response (number, size and vol-
ume) was evaluated on MRI in consensus by two senior 
radiologists. For initial treatment planning, unenhanced 
and contrast-enhanced [application of 0.1 mmol of gado-
pentate dimeglumine (Magnevist, Schering, Berlin, Ger-
many) per kilogram body weight] T1-weighted gradient-
echo sequences (FLASH-2D) with transversal and sagittal 
slice orientation (TR/TE:135/6 ms; FA 80°; FOV 350 
mm; matrix 134 × 256; slice thickness 8 mm) MRI studies 
were carried out for all patients with a conventional 1.5-T 
system (Magnetom Symphony; Siemens, Erlangen, Ger-
many). Additional non-enhanced T2-weighted turbo-spin-
echo (TSE) sequences (TR/TE: 3 800/92 ms; FA 150°; 
FOV 350 mm; matrix 115 × 256; slice thickness 8 mm) 
and contrast-enhanced dynamic VIBE sequences (TR/TE: 
4.5/1.8 ms; FA 15°; FOV 350 mm; matrix 128 × 256; slice 
thickness 8 mm) were used for the differentiation of the 
lesions.
Lipiodol retention in the tumor and the liver paren-
chyma was verified with non-enhanced CT examinations. 
In addition, CT allows optimal comparison between re-
sults on follow-up images in the subsequent sessions and 
can efficiently exclude major post-procedure complica-
tions such as pancreatitis, hepatic infarction, mesenteric 
ischemia, and ascites or ectopic embolization. CT was 
performed 24 h after TACE using the spiral technique (slice 
thickness, 8 mm) on fourth-generation scanners (Somatom 
plus or Somatom plus 4, Siemens, Erlangen, Germany).
Statistical evaluation
For assessment of different risk factors, patients were 
divided into two groups according to the following: (1) 
Presence or absence of PVT; (2) Presence or absence of 
APS; (3) Child-Pugh scores (A or B); (4) Number of fo-
cal lesions (solitary or multiple); and (5) Definition of the 
focal lesions (well defined or ill defined margin). Patients 
were further divided into groups according to the un-
derlying liver pathology (HCV, HBV, alcoholic, toxic and 
cryptogenic cirrhosis). Data were statistically described 
in terms of range, mean ± SD, frequencies (number of 
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Vogl TJ et al. TACE therapy in advanced HCCcases) and relative frequencies (percentages) when appro-
priate. Comparison of quantitative variables between dif-
ferent groups was done using Wilcoxon Mann Whitney U 
test for independent samples. Comparison of quantitative 
variables over the study period was done using Wilcoxon 
matched-pairs test comparisons. A probability value (P 
value) less than 0.05 was considered statistically signifi-
cant. The influence of variables on prognosis was evalu-
ated by univariate analysis. When the result was statistically 
significant, multivariate regression analysis was used to 
analyze the factors influencing the prognosis to avoid any 
confounding interaction between them.
Survival times were calculated beginning with the 
dates of the first TACE treatment using the Kaplan-Meier 
method. The log-rank test was used to determine the sig-
nificance of the difference between patient survival rates 
in different patient groups. 
RESULTS
The treatment protocols were well tolerated by all patients, 
with only minor side effects and no major complications. 
Post-embolization syndrome in the form of nausea and 
vomiting occurred in 9 patients (23%) and a dull aching 
upper abdominal pain persisting for 24 h in 11 patients 
(28.2%). There was no mortality within 30 d from the 
time of TACE.
Local tumor response using RECIST criteria
Local tumor morphologic evaluations according to RE-
CIST criteria were as follows: no patient achieved com-
plete response, partial response in one patient (2.6%), sta-
ble disease in 34 patients (87.1%) and progressive disease 
in 4 patients (10.3%). The comparisons of the local tumor 
response according to RECIST criteria in different patient 
groups are summarized in Table 2.
Local tumor response using volumetric MR imaging as-
sessment
The local tumor response using MR volumetric mea-
surements revealed the following results: tumor volume 
reduction in 17 patients (43.6%) and tumor volume pro-
gression in 22 patients (56.4%). The changes of the tu-
mor volumes after TACE and the local tumor response 
are summarized in Tables 3 and 4.
The local tumor response evaluated using the percent-
age of volume changes between the pre- and post-treat-
ment volumes was statistically significant and influenced 
by the following factors: the presence or absence of PVT, 
presence or absence of APS and tumor margin definition 
(P = 0.018, 0.008 and 0.001, respectively) (using Mann-
Whitney-U-test), as tumor volume regression was detected 
more in the absence of PVT and APS and in tumors with 
well defined margins (Figure 1). Multivariate analysis (using 
multiple regression test) showed that the tumor margin 
definition seems a more significant factor compared to 
the presence of PVT or AP shunts (P = 0.002).
The local tumor response was insignificantly affected 
by the number of focal lesions and Child-Pugh score of 
the patient (P = 0.478 and 0.893, respectively). Correlation 
between the underlying liver pathology and the percentage 
of volume changes between the pre- and post-treatment 
volumes was statistically significant (P = 0.034) (using 
Kruskal Wallis-test). However, correlation between the dif-
ferent patient groups failed to prove statistical significance 
(using Conover-Iman-Test). The changes of the median 
tumor volumes are illustrated in Figure 2. The correlation 
between the pre- and post-treatment tumor volumes for all 
patients is illustrated in a scatter gram (Figure 3).
Survival analysis
The overall survival rates calculated from the time of first 
TACE sessions for all patients at 6, 12 and 18 mo were 
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Figure 1  Magnetic resonance imaging volumetric changes of the median 
tumor volume (mL) in different patient groups. PVT: Portal vein thrombosis; 
AP: Arterioportal.
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Table 2   Response evaluation criteria in solid tumors in different patient groups  n (%)
Total PVT APS Child A Child B Solitary Multiple Well 
defined
Ill defined
Yes No Yes No
No. of patients 39 19 20 7 32 27 12 20 19 20 19
Partial response    1 (2.6) 0  1 (5) 0    1 (3.1) 0  1 (8.3) 0    1 (5.2) 1 (5) 0 
Stable disease 34 (87.1) 18 (94.7) 16 (80)   6 (85.7) 28 (87.5) 24 (88.9) 10 (83.3) 18 (90)   16 (84.2) 17 (85) 17 (89.4)
Progressive disease   4 (10.3) 1 (5.3)   3 (15)   1 (14.2)   3 (9.30)   3 (11.1) 1 (8.3)   2 (10)     2 (10.5)   2 (10)   2 (10.5)
PVT: Portal vein thrombosis; APS: Arterioportal shunt.New research trials utilizing sorafenib have demon-
strated survival extension in two phase Ⅲ trials in North 
America, Europe and in the Asia-Pacific area, which 
respectively reported a median survival after treatment 
of 10.7 and 6.5 mo
[16]. However, drug-related adverse ef-
fects including diarrhea, hand-foot skin reaction, anorexia, 
alopecia, weight loss, dry skin, abdominal pain and voice 
changes have been reported
[17].
Attention has been focused on locoregional approach-
es for the palliative treatment of HCC in recent years. 
Although TACE is widely used in the palliative treatment 
of unresectable HCC, its role remains controversial
[18-20]. It 
has been shown to provide reasonable survival advantages 
in two randomized control trials and a meta-analysis
[21].
Different reports have investigated the predictors of 
survival after TACE for unresectable HCC. These predic-
tors may be related to the tumor burden (number of focal 
lesions, size of the tumor, tumor/liver volume ratio and 
PVT), the liver function (Child-Pugh score), health status 
(constitutional syndrome and Karnofsky index) or may be 
related to the treatment protocol
[8,10,20,22,23]. In a large scale 
study of 8510 patients who underwent TACE, multivari-
ate analyses revealed the following variables to be inde-
pendent predictors of patient prognosis: degree of liver 
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79.5%, 37.5% and 21%, respectively (Figure 4). The me-
dian survival time was 10 mo. There was an insignificant 
difference in the survival rates between different patient 
groups on analysis by log-rank test (PVT: P = 0.653, APS: 
P = 0.822, number of lesions: P = 0.26, margin definition 
of lesion: P = 0.155 and Child-Pugh score: P = 0.09) 
(Figure 4).
DISCUSSION
Despite the remarkable advancement and availability of 
novel curative options, a great proportion of HCCs are 
still not eligible for curative treatment due to advanced tu-
mor stage or poor hepatic functional reserve
[7]. There is no 
evidenced-based knowledge regarding a standard systemic 
chemotherapy protocol that improves the overall survival 
in advanced HCC patients
[14]. Combination chemotherapy 
using different mixtures of doxorubicin, 5-FU, mitomycin 
C, bleomycin, cisplatin, interferon (PIAF), gemcitabine and 
mitoxantrone has been employed in the treatment of ad-
vanced HCC. Although some of the combination regimes 
have shown improved tumor control in phase Ⅱ studies, 
most of them fail to demonstrate any survival advantage 
in randomized phase Ⅲ studies
[15]. 
Vogl TJ et al. TACE therapy in advanced HCC
Table 3  Magnetic resonance imaging volumetric changes of tumors after Transarterial chemoembolization in different patient groups
Total PVT APS Child A Child B Solitary Multiple Well 
defined
Ill defined
Yes No Yes No
No. of patients 39 19 20    7   32   27 12 20 19 20   19
Initial tumor volume (mL)
Range 1.2-1358 1.2-1358 28.8-301.9 28.9-237 1.2-1358 1.1-1355 56.7-1358 1.2-1355 23.4-1358 1.2-301.9 28.8-1358
Mean   227.6    354.5 107 109.2    253.5    162.3 374.5 246 208.2 97.0 365
SD     318.76    418.2      78.5   75.2    345.8    275.8 370.5 317 327.2 60.0 411
Tumor volume 1 mo after the 1st TACE
Range 1.3-1637.5 1.3-1637.5 15.6-334.8 39-239 1.3-637.5 1.3-1500 23.7-1637.5 1.3-1499.7 15.6-1637.5 1.3-334.9 39-1637.5
Mean   244.5    402.6      94.3 126.5    270.3    159.6 435.6 242.6 246.6 65.3 412
SD 369    480.1      72.8   85.0    402.2    284.7 470.0 334.3 411.9 75.3 473
Tumor volume at  the end of treatment
Range 1.6- 2053.4 1.6-2053.4 9.4-403.1 94.5-308 1.6-2053.4 1.6-2053.4 22.5-1637.5 1.6-2053.4 9.4-1637.4 1.6-403.1 83-2053.4
Mean   286.1 486      96.2 188.6    307.5    197.4 485.6 280.8 291.7 74.3    509.1
SD   453.2    583.7 100   72.5 490 391 534.2 452.9 465.8 69.5 568
PVT: Portal vein thrombosis; APS: Arterioportal shunt; TACE: Transarterial chemoembolization
Table 3   Magnetic resonance imaging volumetric changes of tumors after transarterial chemoembolization in different patient groups    
Table 4  Local tumor response using volumetric magnetic resonance imaging analysis  n (%)
PVT: Portal vein thrombosis; APS: Arterioportal shunt; TACE: Transarterial chemoembolization
Total PVT APS Child A Child B Solitary Multiple Well 
defined
Ill defined
Yes No Yes No
No. of patients 39 19 20 7 32 27 12 20 19 20 19
Tumor volume reduction 
after last TACE session
17 (43.6) 5 (26.3) 12 (60) 0 (0) 17 (53.1) 13 (48.1) 4 (33.3)   9 (45)   8 (42.1) 13 (65)     4 (21.05)
Tumor volume progression 
after last TACE session
22 (56.4) 14 (73.7)   8 (40)     7 (100) 15 (46.9) 14 (51.9) 8 (66.7) 11 (55) 11 (57.9)   7 (35) 15 (78.9)damage, maximum tumor size, number of lesion(s) and 
portal vein invasion
[8]. Portal vein invasion showed much 
higher risks than the other variables.
The endpoint in cancer research is overall survival. 
Nonetheless, other potential endpoints, such as response 
rate and time to progression, are currently used. In this 
study, the predictors of local tumor response after TACE 
were evaluated, as well as the role of TACE in local tumor 
control for unresectable advanced HCC. Since volumetric 
quantification can lead to a different assessment result 
compared with uni- and bi-dimensional measurement 
techniques
[24], the local tumor response to the TACE treat-
ment was evaluated using both RECIST criteria and MRI 
volumetric measurements. According to RECIST criteria, 
tumor stability was achieved in 34/39 patients (87.1%), 
and partial response in 1 patient (2.6 %), while progres-
sion occurred in 4 patients (10.3%) and, by volumetric 
measurements, reduction of the tumor volume occurred 
in 17 patients (43.6%) and progression in (56.4%), taking 
into consideration the inclusion of advanced pretreat-
ment tumor stage regarding the size, number and portal 
vein invasion. This may emphasize the role of TACE in 
local tumor control even in the advanced stages of HCC. 
Univariate analysis revealed the following 4 variables as 
significant prognostic factors: PVT, APS, tumor margin 
definition and underlying liver pathology (Figures 5 and 
6). The clinical significance of the presence of PVT, APS 
and tumor margin ill definition is clearly demonstrated 
by the progressive increase in the corresponding median 
tumor volumes at the end of TACE treatment (Figure 1). 
Multivariate analysis showed that the tumor margin ill def-
inition affects the local tumor response more significantly 
compared to the presence of PVT or AP shunts.
TACE has been limited in palliative treatment of cases 
associated with major portal vein (PV) invasion due to the 
possibility of liver failure following embolization and that 
it may predispose to hepatic infarction. Transcatheter ar-
terial chemo infusion (TACI) has been an option in such 
cases
[25]. However, recent studies have shown that TACE 
using less aggressive embolization can be performed 
safely in patients with major PV thrombosis with no in-
crease in morbidity or mortality
[26-28]. The current study 
included patients with partial thrombosis of the main PV 
or thrombosis of one of its lobar branches or segmen-
tal branches. The procedure was tolerated by all patients 
and none of the patients developed major complications 
that required prolonged hospitalization. Chung et al
[29] ex-
plained the prognostic significance of PVT by suggesting 
that the presence of tumor thrombi in the PV results in 
extensive tumor spread throughout the liver. 
Arterioportal shunts associated with HCC have been 
reported in about 28.8% to 63.2% of HCCs. Ngan et al
[30]   
explained the poor prognostic clinical significance by sug-
gesting that the shunt flow to the portal vein aggravates 
the portal venous pressure, which induces life-threatening 
conditions such as esophageal varix, ascites and hepatic 
encephalopathy. In this present study 7/39 patients (17.9%) 
had associated APS, six of these cases were associated with 
ill defined tumor margin and four cases were associated 
with PVT. The MR volumetric measurements revealed 
progression of the tumor in the 7 patients (100%) and the 
percentage of volume changes between both groups (APS 
and no APS) were statistically significant. Huang et al
[31] 
explained poor response to TACE by the fact that during 
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Figure 3  Scatter gram. Correlation between the pre- and post-treatment volume. 
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Figure 4  Kaplan-Meier survival curve for all patients showing the overall 
survival rates calculated from the time of first transarterial chemoemboli-
zation sessions. The estimated survival rates at 6, 12 and 18 mo were 79.5%, 
37.5% and 21%, respectively, with a median survival time of 10 mo. Kaplan-
Meier with confidence P = 0.95, 
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Figure 2  Magnetic resonance imaging volumetric changes of the median 
tumor volume (mL) according to the underlying liver pathology. HBV: 
Hepatitis B virus; HCV: Hepatitis C virus.
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Vogl TJ et al. TACE therapy in advanced HCCTACE, oil emulsion may be diverted into the portal vein 
branches and delivered to non-tumor hepatic tissue instead 
of being deposited intratumorally. Although the univariate 
analysis revealed a statistical significance between the un-
derlying liver pathology and the local tumor response, the 
multivariate analysis failed to prove the clinical significance, 
probably because of the sample size and the registered data 
which are located out of the overlapping area statistically.
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Figure 5  A 76-year-old female patient, hepatitis C virus liver cirrhosis. A: Axial magnetic resonance imaging (MRI) T1 WI showing an isointense subcapsular 
hepatocellular carcinoma at segment 8 (white arrow); B: Digital subtraction angiography before the 1st transarterial chemoembolization (TACE) showing a large tumor 
blush at segment 8 (white arrow); C: Computed tomography (CT) after the first embolization showing dense Lipiodol uptake by the tumor (white arrow); D: Hepatic ar-
teriography after the 5th TACE session showing occluded feeding arteries and Lipiodol concentration within the tumor (white arrow); E: CT after the last TACE session 
showing reduction of the tumor size (> 50%) by MRI volumetry (white arrow).
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Figure 6  A 58-year-old male patient with alcoholic cirrhosis. A: Axial magnetic resonance imaging (MRI) T1 post contrast weighted image showing an ill defined 
mass in segments 5 and 6 (white arrows). Note enhancement of the portal vein (black arrow) in the arterial phase (black arrow head at the aorta) denoting an un-
derlying arterioportal shunt; B: Digital subtraction angiography showing opacified portal vein (white arrows) during the arterial phase (APS) (white arrows); C: Digital 
subtraction angiography during the last (6th) transarterial chemoembolization (TACE) showing the APS with markedly dilated and partially thrombosed portal vein (white 
arrows); D, E: Axial MRI T1 post contrast after the last TACE showing tumor infiltration of the dilated main portal vein (white arrow in Figure 6D) and progression of the 
tumor size (> 20%) by MRI volumetry (white arrows in Figure 6E) (white arrows).
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Vogl TJ et al. TACE therapy in advanced HCCLimitations of this study are the retrospective design 
and the heterogeneous population. However, this study 
at least illustrates the role of TACE in local tumor con-
trol of unresectable HCC, even in advanced cases, and 
the prognostic factors affecting the tumor response.
In conclusion, TACE may be applied in the palliative 
treatment of patients with unresectable advanced HCC 
for local tumor control. The local tumor response to 
TACE is significantly affected by the presence or absence 
of portal vein thrombosis, arterioportal shunt, tumor 
margin definition and the underlying liver pathology. 
COMMENTS
Background
To date, there is no evidence-based knowledge regarding a standard systemic 
chemotherapy protocol that improves the overall survival in advanced hepatic 
cancer (HCC). Attention has been focused on regional liver approaches for 
the palliative treatment of HCC in recent years, including transarterial hepatic 
chemoembolization (TACE). This therapy been shown to provide reasonable 
survival advantages in two randomized control trials and a meta-analysis. 
However, the factors that determine tumor response under the effect of local 
chemotherapy are still under research and evaluation.
Research frontiers
This research focused on the vascular factors that may affect the tumor re-
sponse and patient survival in patients undergoing TACE therapy in advanced 
HCC. Both portal vein thrombosis (PVT) and arterioportal shunts (APS) were 
found to be statistically significant factors influencing reduced tumor respon-
siveness to TACE therapy. Other pathological factors which may determine the 
tumor end response are the underlying liver pathology, Child-Pugh status and 
tumor margin definition. 
Innovations and breakthroughs
The study concludes that TACE may be exploited safely for palliative tumor 
control in patients with advanced unresectable HCC; however tumor response 
is significantly affected by the presence or absence of PVT and APS. 
Terminology
Transarterial Chemoembolization is a minimally invasive therapeutic procedure 
which consists of: catheterization of the hepatic artery to inject the chemo-
therapeutic medications selectively in the feeding vessels of the liver tumor. 
The therapeutic medications consist of chemotherapeutic agent (which inhibits 
tumor cell proliferation) in a mixture with occlusive material (to block the feeding 
vessels of the tumor). Both agents work together to suppress tumor activity and 
kill tumor cells. Portal vein thrombosis: thrombosis of the major blood vessel of 
the liver that carries the nutritive materials from the gastrointestinal tract to be 
metabolized in the liver. The hepatic portal vein is responsible for 75% of blood 
supply to the liver. Arterioportal shunt: This is an abnormal communication be-
tween the hepatic artery and portal vein tributaries.
Peer review
I think this article is well written.
REFERENCES
1  Llovet JM, Bruix J. Novel advancements in the management 
of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 Suppl 
1: S20-S37
2  Llovet JM, Sala M. Non-surgical therapies of hepatocellular 
carcinoma. Eur J Gastroenterol Hepatol 2005; 17: 505-513
3  Ishii H, Okada S, Nose H, Okusaka T, Yoshimori M, 
Takayama T, Kosuge T, Yamasaki S, Sakamoto M, Hirohashi 
S. Local recurrence of hepatocellular carcinoma after 
percutaneous ethanolinjection. Cancer 1996; 77: 1792-1796
4  Sartori S, Tombesi P, Macario F, Nielsen I, Tassinari D, 
Catellani M, Abbasciano V. Subcapsular liver tumors treated 
with percutaneous radiofrequency ablation: a prospective 
comparison with nonsubcapsular liver tumors for safety and 
effectiveness. Radiology 2008; 248: 670-679
5  Ishida T, Murakami T, Shibata T, Inoue Y, Takamura M, 
Niinobu T, Sato T, Nakamura H. Percutaneous microwave 
tumor coagulation for hepatocellular carcinomas with 
interruption of segmental hepatic blood flow. J Vasc Interv 
Radiol 2002; 13: 185-191
6  Vogl TJ, Straub R, Eichler K, Woitaschek D, Mack MG. 
Malignant liver tumors treated with MR imaging-guided laser-
induced thermotherapy: experience with complications in 899 
patients (2,520 lesions). Radiology 2002; 225: 367-377
7  Molinari M, Kachura JR, Dixon E, Rajan DK, Hayeems EB, 
Asch MR, Benjamin MS, Sherman M, Gallinger S, Burnett B, 
Feld R, Chen E, Greig PD, Grant DR, Knox JJ. Transarterial 
chemoembolisation for advanced hepatocellular carcinoma: 
results from a North American cancer centre. Clin Oncol (R 
Coll Radiol) 2006; 18: 684-692
8  Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, 
Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka 
Y. Prospective cohort study of transarterial chemoembolization 
for unresectable hepatocellular carcinoma in 8510 patients. 
Gastroenterology 2006; 131: 461-469
9  Cammà C, Schepis F, Orlando A, Albanese M, Shahied L, 
Trevisani F, Andreone P, Craxì A, Cottone M. Transarterial 
chemoembolization for unresectable hepatocellular carcinoma: 
meta-analysis of randomized controlled trials. Radiology 2002; 
224: 47-54
10  Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, 
Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial 
embolisation or chemoembolisation versus symptomatic 
treatment in patients with unresectable hepatocellular carcinoma: 
a randomised controlled trial. Lancet 2002; 359: 1734-1739
11  Zhang JW, Feng XY, Liu HQ, Yao ZW, Yang YM, Liu B, Yu 
YQ. CT volume measurement for prognostic evaluation of 
unresectable hepatocellular carcinoma after TACE. World J 
Gastroenterol 2010; 16: 2038-2045
12  Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of 
Interventional Radiology clinical practice guide lines. J Vasc 
Interv Radiol 2003; 227: 407-413
13  Padhani AR, Ollivier L. The RECIST (Response Evaluation 
Criteria in Solid Tumors) criteria: implications for diagnostic 
radiologists. Br J Radiol 2001; 74: 983-986
14  Palmer DH, Hussain SA, Johnson PJ. Systemic therapies for 
hepatocellular carcinoma. Expert Opin Investig Drugs 2004; 
13: 1555-1568
15  Yau T, Chan P, Epstein R, Poon RT. Evolution of systemic 
therapy of advanced hepatocellular carcinoma. World J 
Gastroenterol 2008; 14: 6437-6441
16  Di Lorenzo G, Imbimbo M, Leopardo D, Marciano R, 
Federico P, Buonerba C, Salvatore B, Marinelli A, Palmieri G. 
A long-lasting response to sorafenib treatment in an advanced 
hepatocellular carcinoma patient. Int J Immunopathol Pharmacol 
2010; 23: 951-954
17  Keating GM, Santoro A. Sorafenib: a review of its use in 
advanced hepatocellular carcinoma. Drugs 2009; 69: 223-240
18  Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, 
Ayuso C, Vargas V, Rodés J, Bruix J. Randomized controlled 
trial of interferon treatment for advanced hepatocellular 
carcinoma. Hepatology 2000; 31: 54-58
19  Llovet JM, Bruix J. Systematic review of randomized trials for 
unresectable hepatocellular carcinoma: Chemoembolization 
improves survival. Hepatology 2003; 37: 429-442
20  O’Suilleabhain CB, Poon RT, Yong JL, Ooi GC, Tso WK, Fan 
ST. Factors predictive of 5-year survival after transarterial 
chemoembolization for inoperable hepatocellular carcinoma. 
Br J Surg 2003; 90: 325-331
21  Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan 
ST, Wong J. Randomized controlled trial of transarterial 
lipiodol chemoembolization for unresectable hepatocellular 
carcinoma. Hepatology 2002; 35: 1164-1171
22  Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, 
Silva S, Fatela N, Glória H, Marinho R, Távora I, Ramalho F, 
1274 March 14, 2011|Volume 17|Issue 10| WJG|www.wjgnet.com
 COMMENTS
Vogl TJ et al. TACE therapy in advanced HCCde Moura MC. Treatment and prognostic factors in patients 
with hepatocellular carcinoma. Liver Int 2006; 26: 680-687
23  Ikeda M, Okada S, Yamamoto S, Sato T, Ueno H, Okusaka T, 
Kuriyama H, Takayasu K, Furukawa H, Iwata R. Prognostic 
factors in patients with hepatocellular carcinoma treated by 
transcatheter arterial embolization. Jpn J Clin Oncol 2002; 32: 
455-460
24  Sohaib SA, Turner B, Hanson JA, Farquharson M, Oliver RT, 
Reznek RH. CT assessment of tumour response to treatment: 
comparison of linear, cross-sectional and volumetric 
measures of tumour size. Br J Radiol 2000; 73: 1178-1184
25  Kim JH, Yoon HK, Kim SY, Kim KM, Ko GY, Gwon DI, 
Sung KB. Transcatheter arterial chemoembolization vs. 
chemoinfusion for unresectable hepatocellular carcinoma 
in patients with major portal vein thrombosis. Aliment 
Pharmacol Ther 2009; 29: 1291-1298
26  Kothary N, Weintraub JL, Susman J, Rundback JH. 
Transarterial chemoembolization for primary hepatocellular 
carcinoma in patients at high risk. J Vasc Interv Radiol 2007; 
18: 1517-1526; quiz 1527
27  Kiely JM, Rilling WS, Touzios JG, Hieb RA, Franco J, Saeian 
K, Quebbeman EJ, Pitt HA. Chemoembolization in patients 
at high risk: results and complications. J Vasc Interv Radiol 
2006; 17: 47-53
28  Georgiades CS, Hong K, D’Angelo M, Geschwind JF. Safety 
and efficacy of transarterial chemoembolization in patients 
with unresectable hepatocellular carcinoma and portal vein 
thrombosis. J Vasc Interv Radiol 2005; 16: 1653-1659
29  Chung JW, Park JH, Han JK, Choi BI, Han MC. Hepatocellular 
carcinoma and portal vein invasion: results of treatment with 
transcatheter oily chemoembolization. AJR Am J Roentgenol 
1995; 165: 315-321
30  Ngan H, Peh WC. Arteriovenous shunting in hepatocellular 
carcinoma: its prevalence and clinical significance. Clin 
Radiol 1997; 52: 36-40
31  Huang MS, Lin Q, Jiang ZB, Zhu KS, Guan SH, Li ZR, 
Shan H. Comparison of long-term effects between intra-
arterially delivered ethanol and Gelfoam for the treatment 
of severe arterioportal shunt in patients with hepatocellular 
carcinoma. World J Gastroenterol 2004; 10: 825-829
S- Editor  Sun H    L- Editor  Logan S    E- Editor  Ma WH
Vogl TJ et al. TACE therapy in advanced HCC
1275 March 14, 2011|Volume 17|Issue 10| WJG|www.wjgnet.com